mediarelease

IBA (Ion Beam Applications S.A.) announced today that it has closed with
ProCure Treatment Centers, Inc. the contract to supply a proton therapy
system at the ProCure Proton Therapy Center in Somerset, New Jersey,
USA. The contract is financed and in full force.

IBA has built its reputation as a leader in technology innovation and
operational excellence. Today, despite a challenging economic climate,
IBA continues to demonstrate leadership and experience also in
developing unique financing solutions together with its banking network.
This facilitates the acquisition process for its clients.

The Proton Therapy system will include four treatment rooms - a
combination of gantry (isocentric rotating frames), inclined beam and
fixed-beam rooms - with the latest options for patient positioning and
the IBA Universal Nozzle technology, including the latest Pencil Beam
Scanning. The relationship will also include a long-term service and
maintenance agreement. The center is expected to treat its first patient
in 2012.

“We are excited about working with IBA on another proton therapy
center,” said Hadley Ford, ProCure’s Chief Executive Officer. “IBA
is the industry leader in proton therapy technology and we have been
able to count on them to develop innovations with a focus on precision,
safety and patient comfort.”

Proton Therapy is increasingly considered as the best radiotherapy for
cancer due to its superior dose distribution. Protons deposit the
majority of their effective energy within a precisely controlled range,
directly within the tumor, and better spare healthy surrounding tissue.
Higher doses can be delivered to the tumor without increasing the risks
of side effects and long term complications, improving outcomes and
quality of life for patients. Unfortunately, very few patients can yet
benefit from this type of treatment around the world.

IBA is continuing its efforts to make Particle Therapy available
worldwide. Concretely, as of today seven proton therapy centers, built
by IBA, are treating patients every day in the USA and Asia. Beside
them, IBA manages the simultaneous construction and installation of nine
additional proton therapy centers, five in USA and four in Europe.

ABOUT PROCURE TREATMENT CENTERS, INC.

ProCure Treatment Centers, Inc., based in Bloomington, Ind., was founded
in 2005 to improve the lives of patients with cancer by increasing
access to proton therapy. ProCure collaborates with leading radiation
oncology practices and hospitals and provides management leadership and
a comprehensive approach for the design, construction, financing,
staffing, training and day-to-day operations of world-class proton
therapy centers. ProCure’s solution reduces the time, cost and effort
necessary to create a facility. ProCure is the only company in the world
with a center open and treating patients (Oklahoma City), another under
construction in suburban Chicago (Warrenville) to open in early 2011,
and four others in development (Seattle; Somerset, N.J.; South Florida;
and Detroit). ProCure’s Training and Development Center is the first
facility in the world dedicated exclusively to proton therapy. For more
information, visit www.procure.com.

ABOUT IBA

IBA develops and markets leading-edge technologies, pharmaceuticals and
tailor-made solutions for healthcare with a focus on cancer diagnosis
and therapy. Leveraging on its scientific expertise, IBA is also active
in the field of industrial sterilization and ionization. Listed on the
pan-European stock exchange EURONEXT, IBA is included in the BelMid
Index. (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). Website: www.iba-worldwide.com

save this article as .pdf.